Latest news with #Werewolf
Engadget
4 days ago
- Entertainment
- Engadget
Killer Inn turns Werewolf into a multiplayer action game
Killer Inn is a little bit murder mystery and a little bit third-person action game, and combined, it looks like a lot of fun. Square Enix and developer Tactic Studios revealed Killer Inn during today's Summer Game Fest kickoff stream. A beta for the game is coming to Steam soon and it's available to wishlist now. Killer Inn is a lot like the movie Clue , or the TV show The Traitors , or the social improv game Werewolf , or the video game Spy Party — it's all about uncovering players' true intentions and concealing your own, with a murderous twist. Each round includes 24 players, some of whom are wolves, while the rest are lambs. As a lamb, the players' goal is sniff out the wolves and survive their attacks, and the wolves are out to blend in with the herd, stealthily killing when they can. Each kill leaves behind a clue for other players to find. The game ends when one team has eliminated all members of the opposing group. It isn't pure social strategy — there are various weapons, traps, poisons, bits of armor and masks to use, and a range of characters to choose from. Killer Inn is playable solo or with up to four players.
Elle
17-05-2025
- Entertainment
- Elle
Why Suki Waterhouse Was Not With Robert Pattinson at Cannes
On Saturday, Robert Pattinson walked the red carpet for the premiere of his new film Die, My Love, beside co-star Jennifer Lawrence. Pattinson was in a classic black tux, while Lawrence wore a strapless white gown by Dior made of ruched fabric ,with a tiered skirt that ended in a small train. Pattinson's partner, Suki Waterhouse, did not appear on the red carpet for the movie's premiere. She was most recently seen in New York City at the Met Gala, and may not have been able to make it to Cannes for this year's festival. The couple has a daughter at home who they welcomed in spring of last year. Die, My Love is based on the Ariana Harwicz novel of the same name and stars Jennifer Lawrence as a woman consumed by 'love and madness,' according to a synopsis on Deadline. Pattinson is the object of her obsession, and they are joined on screen by LaKeith Stanfield, Sissy Spacek, and Nick Nolte. On Friday night, Pattinson and Lawrence made an appearance on the red carpet at the Dior at The Hollywood Reporter dinner for the film's cast. It was Lawrence's first time in the spotlight since welcoming her second child with husband Cooke Maroney. In July 2024, Waterhouse spoke to British Vogue about her relationship with the actor, describing how they met. 'I was sure that I'd met him a long time ago, but he didn't think that we had,' she shared, explaining they then did a round of the role playing game Werewolf that was 'very, very intense. There were lots of 'big' characters, real heavy hitters [in the room]. Al Pacino was there. Javier and Penelope were there… and, you know, everyone was really acting.' She continued, 'I think we both sort of have the same slight uncomfortable-ness [and quickly] started giggling at the absurdity of the whole thing,' adding they 'got told off' for laughing and that a director 'separated us because we were laughing too much.' They met up again later that year and began spending time together. Soon they were dating and then discovered they were expecting. She shared that while giving birth, Pattinson made her a rap playlist. 'He was there with me and like all dads, he was really nervous, but for someone who's quite an anxious person, he's been very calm,' she said. '[He's] the dad I could have hoped for. I mean a dad and his daughter? It's an actual love story.'
Newsweek
08-05-2025
- Entertainment
- Newsweek
The Traitors Season 4 - Everything We Know, Release Date, Trailer
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Entertainment gossip and news from Newsweek's network of contributors The Traitors is one of the best reality shows on TV, and it's just getting started. Here's when you can expect The Traitors Season 4 to release, as well as where to watch it, and what any format changes could look like. If you haven't managed to catch it yet, The Traitors is a TV-friendly take on the popular party game Mafia (also known as Werewolf). Players are assigned roles, whether traitor or faithful, and seek to eliminate the other team by plotting, collaborating, and backstabbing. Each night, there's a meeting to vote out one player suspected of being a traitor - and this is where the fireworks happen. Premiering in January 2023, The Traitors has gone on to widespread acclaim, even winning Emmys for Outstanding Reality Competition Program and Outstanding Host for a Reality or Reality Competition Program (Alan Cumming on cunning form). Alan Cumming hosts The Traitors Alan Cumming hosts The Traitors Courtesy Peacock Read on for everything we know about The Traitors Season 4. What is The Traitors? The Traitors is a reality TV show based on its British counterpart, which is itself based on the Dutch series De Verraders (2021 - present). It follows the structure of the popular party game Mafia, in which players plot against each other to become the last one remaining. The Traitors UK premiered on 29 November 2022. Both it and The Traitors US are produced by Studio Lambert for the BBC and Peacock, sharing the same format, rules, and location. Is There The Traitors Season 4? Yes, in August 2024, the show was renewed for two additional seasons. That means we're getting The Traitors Season 4 and The Traitors Season 5. The news came ahead of Season 3's release, on August 14, 2024, with Peacock announcing the show would return for at least two more seasons. When is The Traitors Season 4 Release Date? The Traitors Season 4 does not yet have a release date, but it will likely air in January 2026. An early 2026 window aligns it with each previous season, which all released in a similar time frame. Has The Traitors Season 4 Been Filmed? Not yet. The Traitors Season 4 will likely film later in 2025, readying it for an early 2026 release date. Where to Watch The Traitors Season 4? You can watch The Traitors Season 4 on Peacock, as well as all three previous seasons. It's a Peacock exclusive, so that platform is the only place to catch it. Episodes are streamed every Thursday at 6 pm PT/9 pm ET. The Traitors Season Overview Here's when the previous seasons of The Traitors was released, and how long each one ran for. The Traitors Season 1: January 12, 2023 - February 28, 2023 The Traitors Season 2: January 12, 2024 - March 7, 2024 The Traitors Season 3: January 9, 2025 - March 6, 2025 Will Alan Cumming host Season 4 of The Traitors? Yes, the iconic Alan Cumming is back in the hotseat to host The Traitors Season 4. Not only did he win the Emmy for Outstanding Host for a Reality or Reality Competition Program, but he also serves as a producer on the show. Is there a Trailer for The Traitors Season 4? No. The Traitors Season 4 hasn't been filmed, with a shooting date set for mid-2025. That means the first trailer will likely drop near the end of 2025. Is There a Season 5 of The Traitors? Yes, you can expect even more of The Traitors. Peacock has greenlit two additional seasons, announcing Season 4 and Season 5 in August 2024. The Traitors Season 3 Winners The Traitors Season 3 winners are Dolores Catania, Dylan Efron, Gabby Windey and Lord Ivar Mountbatten. It was the first time in The Traitors history where four contestants won. The four Faithfuls split the prize pot evenly after voting to end the game in the first round of the Fire of Truth.
Yahoo
05-05-2025
- Business
- Yahoo
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the 'Company' or 'Werewolf') (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that management will participate in the following upcoming investor conferences in the month of May: The Citizens Life Sciences Conference 2025Date: Thursday, May 8, 2025 Time: 10:00am ETLocation: New York Hilton Midtown Management will participate in a fireside chat Bank of America Securities 2025 Health Care ConferenceDate: Wednesday, May 14, 2025 Time: 3:15pm PTLocation: The Encore Hotel, Las Vegas, NVManagement will participate in a fireside chat Live webcast links for the fireside chats will be available at Archived replays will be available for approximately 90 days following the respective conferences. About Werewolf Therapeutics: Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf's INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company's most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved. Investor Contact Dan FerryLifeSci Advisors617.430.7576daniel@ Media Contact: Amanda SellersDeerfield Company Contact: Timothy TrostChief Financial OfficerWerewolf Therapeuticsttrost@ in to access your portfolio
Yahoo
05-05-2025
- Business
- Yahoo
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
- Data reveal WTX-921 is efficacious in a mouse colitis model, resulting in reduced tissue damage and inflammatory cytokine production - - Findings offer a more detailed understanding of WTX-921's anti-inflammatory impact on the immune landscape in the inflamed colon - WATERTOWN, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the 'Company' or 'Werewolf') (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced a poster presentation further characterizing its conditionally-activated IL-10 INDUKINE molecule, WTX-921, at IMMUNOLOGY2025, the annual meeting of the American Association of Immunologists (AAI) taking place May 3-7 in Honolulu, Hawaii. Werewolf's findings are summarized in a poster titled, 'Development of WTX-921, A Conditionally Active IL-10 INDUKINETM Molecule for the Treatment of Inflammatory Bowel Disease' (Board #1230). The results build on initial data presented at the 2024 AAI Annual Meeting, which revealed preliminary proof-of-concept for its IL-10 INDUKINE molecule as a potential prodrug for IBD treatment. The data corroborate the preferential cleavage of inflammatory disease linkers by inflamed human IBD tissue samples and reduced colitis in a murine IBD model as previously observed. New results also highlight WTX-921's effective masking of IL-10 via its optimized IL-10 blocking domain, which prevents the peripheral off-tissue pharmacodynamic effects of IL-10. The CDC estimates that 7 million people worldwide had IBD in 2024, and while clinical studies in IBD involving IL-10 have shown promise, they are consistently hampered by dose-dependent adverse events. 'Our findings validate the potential of WTX-921, a first-of-its-kind targeted IL-10 therapy, to modulate disease-driving innate and adaptive immune responses implicated in IBD,' said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics. 'WTX-921 is a novel IL-10 INDUKINE molecule specifically engineered to overcome the significant toxicities associated with systemic IL-10 therapy and deliver this potent anti-inflammatory agent to inflamed colon tissue, which has clear implications for IBD patients in need of better treatment options.' WTX-921 treatment demonstrated efficacy in the ACT animal model of colitis over a duration of 4 weeks, preventing weight loss and resulting in reduced Disease Activity Index (DAI) scores. WTX-921 also inhibited inflammation, evidenced by a decrease in the infiltration/expansion of immune cells (including CD4+ effector T cells and myeloid cells) and reduced RNA levels of inflammatory cytokines within the colon of treated animals. The poster can be viewed in person on Tuesday, May 6, 2025, on board number 1230, with Werewolf delegates present from 1:15-2:30pm to answer questions. The poster will also be available on our website at About WTX-921: WTX-921 is a novel, first-of-its-kind IL-10 INDUKINE™ molecule being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory diseases. Engineered to overcome the significant toxicities associated with systemic IL-10 delivery, WTX-921 is conditionally activated and is specifically designed for the selective delivery of native IL-10 to inflamed tissues, providing therapeutically-relevant exposure while minimizing systemic toxicity in preclinical models. Preclinical data demonstrate that WTX-921 has the potential to block several disease-driving effector molecules and cytokines, eliciting a multipronged effect by inhibiting disease-driving innate and adaptive immune cell populations. About Werewolf Therapeutics:Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf's INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company's most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Werewolf's strategy, future operations, prospects, plans, and objectives of management; the expected timeline for the preclinical and clinical development of product candidates and the availability of data from such preclinical and clinical development; the potential activity and efficacy of product candidates in preclinical studies and clinical trials; and the anticipated safety profile of product candidates constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'aim,' 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'design,' 'designed to,' 'engineered,' 'estimate,' 'expect,' 'goal,' 'intend,' 'may,' 'might,' 'objective,' 'ongoing,' 'plan,' 'positioning itself to,' 'potential,' 'predict,' 'project,' 'promise,' 'should,' 'target,' 'will,' 'working to,' or 'would,' or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the development of product candidates, including the conduct of research activities, and the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; as well as the risks and uncertainties identified in the 'Risk Factors' section of the Company's most recent Form 10-K filed with the Securities and Exchange Commission (SEC), and in subsequent filings the Company may make with the SEC. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release. WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved. Investor ContactDan FerryLifeSci Advisors617.430.7576daniel@ Media Contact:Amanda SellersDeerfield Company Contact:Timothy TrostChief Financial OfficerWerewolf Therapeuticsttrost@
